"2026-01-02 17:52:51","AXSM","178.69","9","$4.2B","6.62","168.77","198.54","FDA acceptance of sNDA for AXS-05 (Alzheimer's Agitation) with Priority Review accelerates commercial timeline to April 2026, significantly de-risking the asset.","OPEN"
"2026-01-02 17:52:53","CORT","38.2","8","$4.8B","6.38","28.63","57.33","FDA approval of Relacorilant for hypercortisolism solidifies Corcept's endocrinology franchise and removes a major overhang.","OPEN"
"2026-01-02 17:52:54","VNDA","8.25","7","$521M","0.61","7.33","10.08","Approval of Tradipitant for motion sickness creates a new niche revenue stream, validating the pipeline after previous setbacks.","OPEN"
"2026-01-02 19:44:04","XERS","7.35","8","$1.23B","0.34","6.83","8.38","Competitor Corcept Therapeutics received an FDA Complete Response Letter (CRL) for Relacorilant on Dec 31, 2025, removing the primary near-term threat to Xeris's Recorlev franchise in Cushing's syndrome. The stock's Jan 2 pullback (-6.8%) erases the initial reaction, offering an attractive entry for a monopoly-extension play.","OPEN"
